Table 10.
Advances of FGFR-TKIs
| Drug | Brand name | Manufacturer | Targets | Applications of diseases | Approved years or current phase of clinical trials |
|---|---|---|---|---|---|
| Erdafitinib | Balversa | Janssen | FGFR1-4 | FGFR2/3-alterated locally advanced or metastatic urothlial cancer that has progressed during or following platinum-containing chemotherapy | 2019 [166] |
| Pemigatinib | Pemazyre | Incyte | FGFR1-3 | Previously treated, unresectable locally advanced or metastatic CCA with FGFR2 fusion+ or other rearrangement | 2020 [167] |
| Investigational drugs | |||||
| Futibatinib | - | Taiho Oncology | FGFR1-4 | FGFR2-rearranged advanced intrahepatic CCA | III (NCT04093362) |
| FGFR1-4 rearranged solid tumors | II (NCT04189445) | ||||
| FGFR-amplifiled MBC | II (NCT04024436) | ||||
| Infigratinib | - | Novartis Oncology | FGFR1-3 |
previously treated advanced FGFR3-rearranged urothlial cancer previously treated advanced FGFR2-rearranged CCA |
II [164] II [168] |
In the last column of “Approval years or current phases of clinical trials”: erdafitinib and pemigatinib were firstly by Food and Drug Administration (FDA); other two drugs are under investigation, we provided current phases of their clinical trials
CCA cholangiocarcinoma, MBC metastatic breast cancer, FGFR fibroblast growth factor receptor
Data source: www.fda.gov, www.drugs.com, and www.clinicaltrials.gov (cutoff date: 19 July 2020)